Read about 2 studies from the April 2023 ASCO Plenary Series, which highlights the use of adagrasib to target several solid tumors with a KRAS G12C mutation and the use of toripalimab to treat stage III non-small cell lung cancer before and after surgery.
Read research from the December 2022 session of the ASCO Plenary Series, which explores combining immunotherapy for advanced non-small cell lung cancer with high PD-L1.
Physical therapist Sarah Saulsberry, PT, COMT, shares how prehabilitation can help people with lung cancer prepare for surgery, how it can help during recovery, and 4 exercises to get started with prehabilitation at home.
In this podcast, Dr. Xiuning Le discusses research from the 2022 North America Conference on Lung Cancer, including 3 studies evaluating targeted therapy treatments for people with non-small cell lung cancer.
Liquid biopsies have become more common in cancer care, particularly for people with non-small cell lung cancer. But what are liquid biopsies, and how are they used? Learn more here about who might need a liquid biopsy and what to expect from the procedure.
In this podcast, 3 Cancer.Net Associate Editors discuss new research presented at the 2022 ASCO Annual Meeting in non-small cell lung cancer, non-Hodgkin lymphoma, Ewing sarcoma, and neuroblastoma.
Read research from the August 2022 session of the ASCO Plenary Series, which features a study that evaluated how common it is for people with lung cancer to have inherited genetic mutations known to increase cancer risk.
In this podcast, experts discuss what people with early-stage lung cancer should know about molecular testing, including what it is, how it may be used in guiding treatment decisions, and several recent studies about its role in treatment planning.
Dr. H. Jack West shares what people with lung cancer should know about biomarker testing, including why it is important in planning treatment and what to expect during the testing process.
Lung cancer survivor Amanda Nerstad shares what it was like receiving a stage 4 diagnosis at age 39, the role genomic testing played in prolonging her quality of life, and how she and her family cope with the diagnosis.
